ra 76Alternative Names: ra76
Latest Information Update: 27 Jan 2017
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Atopic dermatitis
Most Recent Events
- 24 Jan 2017 Kao Corporation and Exam CO plan a clinical trial for Atopic dermatitis in Japan (Topical) (UMIN000025722)
- 18 Jan 2017 Investigation in Atopic dermatitis in Japan (Topical) before January 2017